Completed INTERVENTIONAL NCT06762600

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Subcutaneous Injections of HRS-4729 Injection in Healthy Subjects

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Conditions Overweight or Obesity

Interventions Acetaminophen HRS-4729 injection HRS-4729 injection placebo HRS9531 injection HRS9531 injection placebo

Updated 3 times since 2025 Last updated: Apr 29, 2026 Started: Jan 16, 2025 Primary completion: Mar 12, 2026 Completion: Mar 12, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Overweight or Obesity and is currently completed. Fujian Shengdi Pharmaceutical Co., Ltd. leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

May 4, 2026 — Present [daily]

Completed

Status: Recruiting → Completed · Phase: PHASE1 → None
May 2025 — May 2026 [monthly]

Recruiting PHASE1
Feb 2025 — May 2025 [monthly]

Recruiting PHASE1

First recorded

Jan 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-4729 injection in healthy subjects.

Contact Information

Sponsor contact:

Fujian Shengdi Pharmaceutical Co., Ltd.

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China